益方生物(688382) - 2025 Q1 - 季度财报

Revenue and Profitability - The company's revenue for Q1 2025 was ¥8,188,968.92, a decrease of 4.85% compared to ¥8,606,045.10 in the same period last year[3] - The net profit attributable to shareholders was a loss of ¥57,499,070.16, an improvement from a loss of ¥83,177,667.08 in the previous year[3] - The basic and diluted earnings per share were both -¥0.10, an improvement from -¥0.14 in the same period last year[3] - Net loss for Q1 2025 was CNY 57,499,070.16, an improvement of 30.94% compared to a net loss of CNY 83,177,667.08 in Q1 2024[17] Cash Flow and Liquidity - The net cash flow from operating activities was a negative ¥62,024,952.61, compared to a negative ¥89,720,647.28 in the same period last year[3] - The company’s cash inflow from operating activities totaled CNY 2,477,134.27 in Q1 2025, compared to CNY 5,819,313.65 in Q1 2024[19] - The net cash flow from investing activities was -$259,625,660.39, indicating significant cash outflow for investments[20] - The total cash inflow from financing activities was $6,884,523.15, a decrease from $7,215,958.35 in the previous period[20] - The net cash flow from financing activities was $5,547,866.95, compared to $4,734,864.59 previously, showing an increase[20] - The net increase in cash and cash equivalents was -$316,760,939.87, a significant decline from -$86,199,363.71 in the prior period[20] - The ending balance of cash and cash equivalents was $597,185,628.32, down from $1,129,626,308.86 at the beginning of the period[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,873,297,152.47, a decrease of 2.47% from ¥1,920,817,174.25 at the end of the previous year[4] - Total current assets as of March 31, 2025, amounted to CNY 1,823,300,104.90, a decrease from CNY 1,870,110,649.46 as of December 31, 2024[12] - Total liabilities decreased to CNY 103,054,740.11 in Q1 2025 from CNY 110,033,961.16 in Q1 2024[14] - The equity attributable to shareholders decreased by 2.24%, from ¥1,810,783,213.08 to ¥1,770,242,412.36[4] - Total equity attributable to shareholders was CNY 1,770,242,412.36 in Q1 2025, down from CNY 1,810,783,213.08 in Q1 2024[14] Research and Development - Research and development expenses totaled ¥60,674,466.51, down 28.41% from ¥84,752,226.60 year-on-year[3] - The ratio of R&D expenses to revenue decreased by 243.87 percentage points, from 984.80% to 740.93%[3] - R&D expenses for Q1 2025 were CNY 60,674,466.51, a decrease of 28.43% from CNY 84,752,226.60 in Q1 2024[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,559[8] Inventory and Accounts Management - The company reported a significant increase in inventory, although specific figures were not disclosed[12] - The company is actively managing its accounts payable, which decreased to CNY 54,574,331.75 from CNY 59,963,520.00[13] - Accounts receivable increased to CNY 173,587,883.14 from CNY 165,341,591.44, indicating a growth of approximately 7.5%[12] Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect financial reporting[20] - The company has not disclosed any new product developments or market expansion strategies during this reporting period[11]